Dr. Shao on Prognosis of Patients With HER2+ Breast Cancer

Video

In Partnership With:

Theresa Shao, MD, assistant professor of hematology-oncology, Icahn School of Medicine, Tisch Cancer Institute, Mount Sinai Health System, discusses the prognosis of patients with HER2-positive breast cancer.

Theresa Shao, MD, assistant professor of hematology-oncology, Icahn School of Medicine, Tisch Cancer Institute, Mount Sinai Health System, discusses the prognosis of patients with HER2-positive breast cancer.

The last few years have brought an emergence of new targeted therapies for the neoadjuvant and adjuvant settings, significantly changing the outlook for patients with HER2-positive breast cancer. Looking at the APHINITY study or trials with neratinib (Nerlynx), the invasive disease-free survival rates at 3 and 5 years are on the order of 90%, which is amazing, Shao says.

There also recent studies suggesting that patients with HER2-positive breast cancer may be doing better than other subtypes of breast cancer, or at least as well as patients with estrogen receptor—positive or HER2-negative disease. This is completely different than a decade ago, Shao notes, when a diagnosis of HER2-positive disease was seen as an aggressive, poor prognosis for which there were limited treatment options. Now, agents like trastuzumab (Herceptin) and pertuzumab (Perjeta)—and most recently, ado-trastuzumab emtansine (T-DM1; Kadcyla)—are prolonging survival for these patients and even hinting at curative strategies.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD